Screening decreases prostate cancer death:  first analysis of the1988  Quebec Prospective Randomized Controlled Trial

Barratt, Alexandra L; Coates, Alan S

doi:10.5694/j.1326-5377.2004.tb06240.x

Topics

Does early detection (by prostate-specific antigen [PSA] testing and digital rectal examination) and treatment of prostate cancer reduce the risk of death from prostate cancer among men aged 45–80 years invited to screening?

1 School of Public Health, University of Sydney, NSW.
2 The Cancer Council Australia, Sydney, NSW.

Correspondence:

Acknowledgements:

We would like to thank Professor Les Irwig for comments on earlier drafts of this article.

Competing interests:

None identified.

1. Barratt AL, Irwig L, Glasziou P, et al. Users’ guides to the medical literature. XVII. How to use guidelines and recommendations about screening. JAMA 1999; 281: 2029-2034.
2. Shultz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-412.
3. Cuzick J, Edwards R, Segnan N. Adjusting for non-compliance and contamination in randomized clinical trials. Stat Med 1997; 16: 1017-1029.
4. Glasziou P. Meta-analysis adjusting for compliance: the example of screening for breast cancer. J Clin Epidemiol 1992; 45: 1251-1256.

Online responses are no longer available. Please refer to our instructions for authors page for more information.